HERBAL TREATMENT FOR SIDE EFFECTS OF ANTI ANXIETY DRUGS
Main Article Content
Keywords
.
Abstract
- Anxiety is characterized by feelings of unease, dread, and fear. It could make you sweat, feel fretful and tense, and have a fast heartbeat. It very well may be an ordinary response to strees.
- For example, you could feel restless when confronted with troublesome issue at work, prior to stepping through an exam, or prior to pursuing a significant choice. It can assist you with adapting.
- uneasiness disorder are condition in which you have nervousness that doesn't disappear and can deteriorate over the long run. The reason for tension is obscure. Component, for example, genetic, brain biology, and chemical science, stress, and your current circumstance might assume a part.
the uneasiness issues share self-announced Side effects of tension and dread; uplifted nervousness and dread answering prompts that signal danger, signals that signal no danger, prompts that previously flagged danger, and settings related with danger; raised pressure reactivity to aversive upgrades; attentional predispositions to danger important improvements(1).
References
1. Michelle G. Craske, Ph.D., Scott L. Rauch, M.D., Robert Ursano, M.D etal; What Is an Anxiety Disorder?; Journal of life long leaning in Psychiatry; 9(3); 2011; 369-388.
2. Marc-Antoine Crocq (2015) A history of anxiety: from Hippocrates to DSM, Dialogues in Clinical Neuroscience, 17(3), 2022; 319-325,
3. Smoller JW, Block SR, Young MM; "Genetics of anxiety disorders: the complex road from DSM to DNA"; Depression and Anxiety. 26 (11); 2009; 965–975.
4. National Institute on Drug Abuse (2012-08-03). "Prescription Drug Facts, Effects, Teen Use"; 2012.
5. Derrick K, Green T, Wand T; "Assessing and responding to anxiety and panic in the Emergency Department"; Australasian Emergency Care; 22 (4); 2019; 216–220.
6. Davies MR, Kalsi G, Armour C, Jones IR, McIntosh AM, Smith DJ, et al ; "The Genetic Links to Anxiety and Depression (GLAD) Study: Online recruitment into the largest recontactable study of depression and anxiety"; 2019.
7. Bethany Juby, Adam Felman ; What to known about anxiety; 2023; Anxiety: Symptoms, types, causes, prevention, and treatment (medicalnewstoday.com).
8. DeSousa DA, Moreno AL, Osório FL, et al; Psychometric properties of the dimensional anxiety scales for DSM-5 in a Brazilian community sample; Int J Methods Psychiatr Res.; 26; 2017.
9. Möller E. L., Majdandžić M., Craske M. G. and Bögels S. M.; Dimensional assessment of anxiety disorders in parents and children for DSM-5; International Journal of Methods in Psychiatric Research; 23; 2014; 331–344.
10. Marc-Antoine Crocq ; The history of generalized anxiety disorder as a diagnostic category; Dialogues in Clinical Neuroscience; 19(2); 2017; 107-116.
11. Donald F. Klei; Historical aspects of anxiety; Dialogues in Clinical Neuroscience; 4(3); 2002; 295-304.
12. Crocq MA; A history of anxiety: from Hippocrates to DSM; Dialogues Clin Neurosci; 17(3); 2015; 319-25.
13. Author links open overlay panelWill H. Canu, Monica Elizondo, Joshua J. Broman-Fulks ; History of ADHD traits related to general test and specific math anxiety in college students; Learning and individual difference; 58; 2017; 56-63.
14. Shackman, J. E., Shackman, A. J., & Pollak, S. D. (2007); Physical abuse amplifies attention to threat and increases anxiety in children; Emotion; 7(4); 838–852.
15. Robert L. DuPont, Dorothy P. Rice, Leonard S. Miller et al; Economic costs of anxiety disorders; National Library of Medicine; 2(4); 1996; 167-172.
16. Borwin Bandelow & Sophie Michaelis; Epidemiology of anxiety disorders in the 21st century; Dialogues in Clinical Neuroscience; 17:3; 2015; 327-335.
17. 4-Dinesh Kumar, Zulfiqar Ali Bhat (Dr.) ; Anti-anxiety Activity of Methanolic Extracts of DifferentParts of Angelica archangelica Linn ; Journal of Traditional and Complementary Medicine 2(3), 2012, Pages 235-241.
18. Borwin Bandelow & Sophie Michaelis (2015) Epidemiology of anxiety disorders in the 21st century, Dialogues in Clinical Neuroscience, 17:3, 327-335.
19. M. Harvey Brenner, Dinesh Bhugra ; Acceleration of Anxiety, Depression, and Suicide: Secondary Effects of Economic Disruption Related to COVID-19; Sec. Public Mental Health; 11; 2020.
20. Crocq, Marc-Antoine ; "The History of Generalized Anxiety Disorder as a Diagnostic Category" Dialogues in Clinical Neuroscience. 19(2); 2017; 107–116.
21. Stern, Theodore A.; "Anxiety Disorders (chapter 32)"; Massachusetts General Hospital comprehensive clinical psychiatry. Massachusetts General Hospital (Second ed.); 2015.
22. Anholt GE, Cath DC, van Oppen P et al; "Autism and ADHD symptoms in patients with OCD: are they associated with specific OC symptom dimensions or OC symptom severity?"; Journal of Autism and Developmental Disorders. 40(5); 2010; 580–589.
23. Rasmussen SA, Eisen JL. Epidemiology of obsessive compulsive disorder. The Journal of Clinical Psychiatry; 10-3; 1990.
24. "Panic disorder". UK National Heath Service. 16 February 2021. [ Panic disorder - NHS (www.nhs.uk) ]
25. Markowitz JS, Weissman MM, Ouellette R, Lish JD et al; Quality of Life in Panic Disorder; Arch Gen Psychiatry; 46(11); 1989; 984–992.
26. Phillip R. Zoladz , David M. Diamond; Current status on behavioral and biological markers of PTSD: A search for clarity in a conflicting literature; Neuroscience & Biobehavioral Reviews; 37(5); 2013; 860-895.
27. M.Skogstad, M.Skorstad, A.Lie, H.S.Conradi, T.Heir; Work-related post-traumatic stress disorder; Occupational Medicine; 63(3); 2013; 175–182.
28. Ruscio, A. M.; Brown, T. A.; Chiu, W. T.; Sareen, J.; Stein, M. B.; Kessler, R. C. (2008-01-01). "Social fears and social phobia in the USA: results from the National Comorbidity Survey Replication". Psychological Medicine. 38(1): 15–28.
29. Schneier, F., Goldmark, J.; Social Anxiety Disorder. In: Stein, D., Vythilingum, B. (eds) Anxiety Disorders and Gender; Springer; 2015. https://doi.org/10.1007/978-3-319-13060-6_3
30. Schneier, Franklin R, Blanco, Carlos, Antia, Smita X et al; "The social anxiety spectrum"; Psychiatric Clinics of North America; 25(4); 2002; 757–774.
31. William W Eaton, O Joseph Bienvenu, Beyon Miloyan; Specific phobia; The Lancet Psychiatry; 5(8); 2018; 678-686.
32. Öst, L.-G.; Age of onset in different phobias; Journal of Abnormal Psychology; 96(3); 1987; 223–229.
33. Garcia, René; "Neurobiology of fear and specific phobias"; Learning & Memory; 24(9); 2017; 462–471.
34. Russell G. Vasile M.D., Steven E. Bruce Ph.D., Robert M. Goisman M.D. et al; Results of a naturalistic longitudinal study of benzodiazepine and SSRI use in the treatment of generalized anxiety disorder; Depression and Anxiety; 22(2);2005; 59-67.
35. Scott A, Davidson A, Palmer K. Antidepressant drugs in the treatment of anxiety disorders. Advances in Psychiatric Treatment. 2001;7(4):275-282.
36. Giovanni A. Fava; Rational Use of Antidepressant Drugs; Psychother Psychosom (2014) 83 (4): 197–204.
37. Pierre M. Bet, Jacqueline G. Hugtenburg et al; Side effects of antidepressants during long-term use in a naturalistic setting; European Neuropsychopharmacology; 23(11); 2013; 1443-1451.
38. Richard I. Shader, and David J. Greenblatt; Use of Benzodiazepines in Anxiety Disorders; The New England Journal of Medicine; 1993 Use of Benzodiazepines in Anxiety Disorders | NEJM.
39. Cascade E, Kalali AH; Use of benzodiazepines in the treatment of anxiety; Psychiatry (Edgmont); 2008;5(9):21-2.
40. Cloos, Jean-Marc; Ferreira, Valérie; Current use of benzodiazepines in anxiety disorders; Current Opinion in Psychiatry; 22(1); 2009; 90-95.
41. Barry JJ, Lembke A, Bullock KD. Current Status of the Utilization of Antiepileptic Treatments in Mood, Anxiety and Aggression: Drugs and Devices. Clinical EEG and Neuroscience. 2004;35(1):4-13
42. Mula, Marco MD; Pini, Stefano MD, PhD; Cassano, Giovanni B. MD; The Role of Anticonvulsant Drugs in Anxiety Disorders: A Critical Review of the Evidence. Journal of Clinical Psychopharmacology; 27(3); 2007; 263-272.
43. Kyle M. Kampman; Antiepileptic Drugs in the Treatment of Drug Use Disorders; 1st Edition; 2008; 8.
44. Baibing Chen, Hyunmi Choi b, Lawrence J. Hirsch e al; Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy; Epilepsy & Behavior; 76, 2017, 24-31.
45. Kulbir S. Walia MD, Elizabeth A. Khan MD, Dong H. Ko MD et al; Side Effects of Antiepileptics— A Review; 4(3); 2004; 194-203.
46. Hershenberg, R., Gros, D.F. & Brawman-Mintzer, O.; Role of Atypical Antipsychotics in the Treatment of Generalized Anxiety Disorder; CNS Drugs; 28; 2014; 519–533.
47. Pies R. Should psychiatrists use atypical antipsychotics to treat nonpsychotic anxiety? Psychiatry (Edgmont); 6(6); 2009; 29-37.
48. Nienke C.C. Vulink, Martijn Figee a, Damiaan Denys; Review of atypical antipsychotics in anxiety; European Neuropsychopharmacology; 21(6), 2011; 429-449.
49. Deepak Langade , Subodh Kanchi et al; Efficacy and Safety of Ashwagandha (Withania somnifera) Root Extract in Insomnia and Anxiety:A Double-blind, Randomized, Placebo-controlled Study; Cureus; 11(9); 2019; 1.
50. Deepak Langade MBBS, Vaishali Thakare MBBS et al; Clinical evaluation of the pharmacological impact of ashwagandha root extract on sleep in healthy volunteers and insomnia patients: A double-blind, randomized, parallel-group, placebo-controlled study; Journal of Ethnopharmacology; 264; 2021, 113276.
51. Uttam Kumar Sharma et al; Role of shirodhara with ashwagandha taila in management of stress induced insomnia; Environment Conservation Journal; 16(1&2); 2015.
52. E Ernst, M H Pittler, Efficacy of ginger for nausea and vomiting: a systematic review of randomized clinical trials; BJA: British Journal of Anaesthesia; 84(3); 2000, Pages 367–371.
53. Neerja Tiwari, Manju Singh et al; Harnessing the Neurological properties of Indian Brain Health Booster Brahmi; Frontiers In Medical Chemical;10; 2023; 179-204.
54. Vivek P Chavda, Aavushi B Patel, Disha Vihol et al; Herbal Remedies, Nutraceutial, and Dietary Supplements for COVID-19 Management: An Update; Clinical Complementary Medicine and Pharmacology; 2(1); 2022; 100021.
55. Singh S, Tapadia MG; Ayurvedic formulation Guduchi and Madhuyasti triggers JNK signalling mediated immune response and adversely affect Huntington phenotype; BMC Complement Med. Ther; 22(1); 2022; 265.
56. Dr. Mukesh Kumar Meena; A REVIEW ARTICLE ON MUSCULAR DYSTROPHY AND ITS MANAGEMENT THROUGH AYURVEDA; World Journal of Pharmaceutical Research; 6(11); 378-388.
2. Marc-Antoine Crocq (2015) A history of anxiety: from Hippocrates to DSM, Dialogues in Clinical Neuroscience, 17(3), 2022; 319-325,
3. Smoller JW, Block SR, Young MM; "Genetics of anxiety disorders: the complex road from DSM to DNA"; Depression and Anxiety. 26 (11); 2009; 965–975.
4. National Institute on Drug Abuse (2012-08-03). "Prescription Drug Facts, Effects, Teen Use"; 2012.
5. Derrick K, Green T, Wand T; "Assessing and responding to anxiety and panic in the Emergency Department"; Australasian Emergency Care; 22 (4); 2019; 216–220.
6. Davies MR, Kalsi G, Armour C, Jones IR, McIntosh AM, Smith DJ, et al ; "The Genetic Links to Anxiety and Depression (GLAD) Study: Online recruitment into the largest recontactable study of depression and anxiety"; 2019.
7. Bethany Juby, Adam Felman ; What to known about anxiety; 2023; Anxiety: Symptoms, types, causes, prevention, and treatment (medicalnewstoday.com).
8. DeSousa DA, Moreno AL, Osório FL, et al; Psychometric properties of the dimensional anxiety scales for DSM-5 in a Brazilian community sample; Int J Methods Psychiatr Res.; 26; 2017.
9. Möller E. L., Majdandžić M., Craske M. G. and Bögels S. M.; Dimensional assessment of anxiety disorders in parents and children for DSM-5; International Journal of Methods in Psychiatric Research; 23; 2014; 331–344.
10. Marc-Antoine Crocq ; The history of generalized anxiety disorder as a diagnostic category; Dialogues in Clinical Neuroscience; 19(2); 2017; 107-116.
11. Donald F. Klei; Historical aspects of anxiety; Dialogues in Clinical Neuroscience; 4(3); 2002; 295-304.
12. Crocq MA; A history of anxiety: from Hippocrates to DSM; Dialogues Clin Neurosci; 17(3); 2015; 319-25.
13. Author links open overlay panelWill H. Canu, Monica Elizondo, Joshua J. Broman-Fulks ; History of ADHD traits related to general test and specific math anxiety in college students; Learning and individual difference; 58; 2017; 56-63.
14. Shackman, J. E., Shackman, A. J., & Pollak, S. D. (2007); Physical abuse amplifies attention to threat and increases anxiety in children; Emotion; 7(4); 838–852.
15. Robert L. DuPont, Dorothy P. Rice, Leonard S. Miller et al; Economic costs of anxiety disorders; National Library of Medicine; 2(4); 1996; 167-172.
16. Borwin Bandelow & Sophie Michaelis; Epidemiology of anxiety disorders in the 21st century; Dialogues in Clinical Neuroscience; 17:3; 2015; 327-335.
17. 4-Dinesh Kumar, Zulfiqar Ali Bhat (Dr.) ; Anti-anxiety Activity of Methanolic Extracts of DifferentParts of Angelica archangelica Linn ; Journal of Traditional and Complementary Medicine 2(3), 2012, Pages 235-241.
18. Borwin Bandelow & Sophie Michaelis (2015) Epidemiology of anxiety disorders in the 21st century, Dialogues in Clinical Neuroscience, 17:3, 327-335.
19. M. Harvey Brenner, Dinesh Bhugra ; Acceleration of Anxiety, Depression, and Suicide: Secondary Effects of Economic Disruption Related to COVID-19; Sec. Public Mental Health; 11; 2020.
20. Crocq, Marc-Antoine ; "The History of Generalized Anxiety Disorder as a Diagnostic Category" Dialogues in Clinical Neuroscience. 19(2); 2017; 107–116.
21. Stern, Theodore A.; "Anxiety Disorders (chapter 32)"; Massachusetts General Hospital comprehensive clinical psychiatry. Massachusetts General Hospital (Second ed.); 2015.
22. Anholt GE, Cath DC, van Oppen P et al; "Autism and ADHD symptoms in patients with OCD: are they associated with specific OC symptom dimensions or OC symptom severity?"; Journal of Autism and Developmental Disorders. 40(5); 2010; 580–589.
23. Rasmussen SA, Eisen JL. Epidemiology of obsessive compulsive disorder. The Journal of Clinical Psychiatry; 10-3; 1990.
24. "Panic disorder". UK National Heath Service. 16 February 2021. [ Panic disorder - NHS (www.nhs.uk) ]
25. Markowitz JS, Weissman MM, Ouellette R, Lish JD et al; Quality of Life in Panic Disorder; Arch Gen Psychiatry; 46(11); 1989; 984–992.
26. Phillip R. Zoladz , David M. Diamond; Current status on behavioral and biological markers of PTSD: A search for clarity in a conflicting literature; Neuroscience & Biobehavioral Reviews; 37(5); 2013; 860-895.
27. M.Skogstad, M.Skorstad, A.Lie, H.S.Conradi, T.Heir; Work-related post-traumatic stress disorder; Occupational Medicine; 63(3); 2013; 175–182.
28. Ruscio, A. M.; Brown, T. A.; Chiu, W. T.; Sareen, J.; Stein, M. B.; Kessler, R. C. (2008-01-01). "Social fears and social phobia in the USA: results from the National Comorbidity Survey Replication". Psychological Medicine. 38(1): 15–28.
29. Schneier, F., Goldmark, J.; Social Anxiety Disorder. In: Stein, D., Vythilingum, B. (eds) Anxiety Disorders and Gender; Springer; 2015. https://doi.org/10.1007/978-3-319-13060-6_3
30. Schneier, Franklin R, Blanco, Carlos, Antia, Smita X et al; "The social anxiety spectrum"; Psychiatric Clinics of North America; 25(4); 2002; 757–774.
31. William W Eaton, O Joseph Bienvenu, Beyon Miloyan; Specific phobia; The Lancet Psychiatry; 5(8); 2018; 678-686.
32. Öst, L.-G.; Age of onset in different phobias; Journal of Abnormal Psychology; 96(3); 1987; 223–229.
33. Garcia, René; "Neurobiology of fear and specific phobias"; Learning & Memory; 24(9); 2017; 462–471.
34. Russell G. Vasile M.D., Steven E. Bruce Ph.D., Robert M. Goisman M.D. et al; Results of a naturalistic longitudinal study of benzodiazepine and SSRI use in the treatment of generalized anxiety disorder; Depression and Anxiety; 22(2);2005; 59-67.
35. Scott A, Davidson A, Palmer K. Antidepressant drugs in the treatment of anxiety disorders. Advances in Psychiatric Treatment. 2001;7(4):275-282.
36. Giovanni A. Fava; Rational Use of Antidepressant Drugs; Psychother Psychosom (2014) 83 (4): 197–204.
37. Pierre M. Bet, Jacqueline G. Hugtenburg et al; Side effects of antidepressants during long-term use in a naturalistic setting; European Neuropsychopharmacology; 23(11); 2013; 1443-1451.
38. Richard I. Shader, and David J. Greenblatt; Use of Benzodiazepines in Anxiety Disorders; The New England Journal of Medicine; 1993 Use of Benzodiazepines in Anxiety Disorders | NEJM.
39. Cascade E, Kalali AH; Use of benzodiazepines in the treatment of anxiety; Psychiatry (Edgmont); 2008;5(9):21-2.
40. Cloos, Jean-Marc; Ferreira, Valérie; Current use of benzodiazepines in anxiety disorders; Current Opinion in Psychiatry; 22(1); 2009; 90-95.
41. Barry JJ, Lembke A, Bullock KD. Current Status of the Utilization of Antiepileptic Treatments in Mood, Anxiety and Aggression: Drugs and Devices. Clinical EEG and Neuroscience. 2004;35(1):4-13
42. Mula, Marco MD; Pini, Stefano MD, PhD; Cassano, Giovanni B. MD; The Role of Anticonvulsant Drugs in Anxiety Disorders: A Critical Review of the Evidence. Journal of Clinical Psychopharmacology; 27(3); 2007; 263-272.
43. Kyle M. Kampman; Antiepileptic Drugs in the Treatment of Drug Use Disorders; 1st Edition; 2008; 8.
44. Baibing Chen, Hyunmi Choi b, Lawrence J. Hirsch e al; Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy; Epilepsy & Behavior; 76, 2017, 24-31.
45. Kulbir S. Walia MD, Elizabeth A. Khan MD, Dong H. Ko MD et al; Side Effects of Antiepileptics— A Review; 4(3); 2004; 194-203.
46. Hershenberg, R., Gros, D.F. & Brawman-Mintzer, O.; Role of Atypical Antipsychotics in the Treatment of Generalized Anxiety Disorder; CNS Drugs; 28; 2014; 519–533.
47. Pies R. Should psychiatrists use atypical antipsychotics to treat nonpsychotic anxiety? Psychiatry (Edgmont); 6(6); 2009; 29-37.
48. Nienke C.C. Vulink, Martijn Figee a, Damiaan Denys; Review of atypical antipsychotics in anxiety; European Neuropsychopharmacology; 21(6), 2011; 429-449.
49. Deepak Langade , Subodh Kanchi et al; Efficacy and Safety of Ashwagandha (Withania somnifera) Root Extract in Insomnia and Anxiety:A Double-blind, Randomized, Placebo-controlled Study; Cureus; 11(9); 2019; 1.
50. Deepak Langade MBBS, Vaishali Thakare MBBS et al; Clinical evaluation of the pharmacological impact of ashwagandha root extract on sleep in healthy volunteers and insomnia patients: A double-blind, randomized, parallel-group, placebo-controlled study; Journal of Ethnopharmacology; 264; 2021, 113276.
51. Uttam Kumar Sharma et al; Role of shirodhara with ashwagandha taila in management of stress induced insomnia; Environment Conservation Journal; 16(1&2); 2015.
52. E Ernst, M H Pittler, Efficacy of ginger for nausea and vomiting: a systematic review of randomized clinical trials; BJA: British Journal of Anaesthesia; 84(3); 2000, Pages 367–371.
53. Neerja Tiwari, Manju Singh et al; Harnessing the Neurological properties of Indian Brain Health Booster Brahmi; Frontiers In Medical Chemical;10; 2023; 179-204.
54. Vivek P Chavda, Aavushi B Patel, Disha Vihol et al; Herbal Remedies, Nutraceutial, and Dietary Supplements for COVID-19 Management: An Update; Clinical Complementary Medicine and Pharmacology; 2(1); 2022; 100021.
55. Singh S, Tapadia MG; Ayurvedic formulation Guduchi and Madhuyasti triggers JNK signalling mediated immune response and adversely affect Huntington phenotype; BMC Complement Med. Ther; 22(1); 2022; 265.
56. Dr. Mukesh Kumar Meena; A REVIEW ARTICLE ON MUSCULAR DYSTROPHY AND ITS MANAGEMENT THROUGH AYURVEDA; World Journal of Pharmaceutical Research; 6(11); 378-388.
Article Sidebar
Published
Jan 30, 2024
Article Details
How to Cite
Jainam Shah, Nadim Chhipa, & Pragnesh Patani. (2024). HERBAL TREATMENT FOR SIDE EFFECTS OF ANTI ANXIETY DRUGS. Journal of Population Therapeutics and Clinical Pharmacology, 31(1), 2258–2265. https://doi.org/10.53555/jptcp.v31i1.4768
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Author Biographies
Jainam Shah
Department of Pharmacy, Khyati College of Pharmacy, Palodia, Ahmedabad
Nadim Chhipa
Associate Professor, Department of Pharmaceutical Chemistry, Khyati College of Pharmacy, Palodia, Ahmedabad
Pragnesh Patani
Principal and Professor, Department of Pharmacology, Khyati College of Pharmacy, Palodia, Ahmedabad